Tamar Braxton has announced a new brand partnership with Gilead Sciences. The music veteran will help educate and raise ...

South Africa will buy lenacapavir using Global Fund money. Studies show it can stop infections entirely in young women. But ...

Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

US funding cuts to global HIV prevention efforts are expected to contribute to 4 million deaths and 6 million HIV infections.

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

The money is not nearly enough to put two to four million people per year in South Africa on the lenacapavir jab, and even if it were, the country’s health system won’t be able to roll out the ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for ...

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...